PLACEBO-CONTROLLED, DOUBLE-BLIND, PROSPECTIVE AND RANDOMIZED PHASE III STUDY TO EVALUATE THE EFFECT OF 12-WEEK TREATMENT WITH DHEA (PRASTERONE) + LOW DOSE ACOLBIFENE ON VASOMOTOR SYMPTOMS (HOT FLUSHES) IN POSTMENOPAUSAL WOMEN

Registry ID

ERC-249

Source registry

HEALTH_CANADA

Status

Pending

Phase

PHASE3

Study type

INTERVENTIONAL

Sponsor

ENDOCEUTICS INC

Last update

2015-05-08

Conditions

• VASOMOTOR SYMPTOMS

Related clinical trials

• A RANDOMIZED, PLACEBO-CONTROLLED, DOUBLE-BLIND, PHASE 3 CLINICAL STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF FEZOLINETANT FOR TREATMENT OF MODERATE TO SEVERE VASOMOTOR SYMPTOMS (HOT FLASHES) IN WOMEN WITH STAGE 0 TO 3 HORMONE RECEPTOR-POSITIVE BREAST CANCER WHO ARE RECEIVING ADJUVANT ENDOCRINE THERAPY
• A DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED MULTICENTER STUDY TO INVESTIGATE EFFICACY AND SAFETY OF ELINZANETANT FOR THE TREATMENT OF VASOMOTOR SYMPTOMS CAUSED BY ADJUVANT ENDOCRINE THERAPY, OVER 52 WEEKS AND OPTIONALLY FOR ADDITIONAL UP TO 3.5 YEARS IN WOMEN WITH, OR AT HIGH RISK FOR DEVELOPING HORMONE-RECEPTOR POSITIVE BREAST CANCER
• THE EFFECT OF CONJUGATED ESTROGENS/ BAZEDOXIFENE (CE/ BZA) ON PERI- AND POSTMENOPAUSAL MOOD AND ANXIETY SYMPTOMS: A PILOT STUDY.

View on source registry